Unaudited Financial Results for the quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics reported its Q1 FY26 results with consolidated revenue from operations rising to ₹524.80 lakhs from ₹463.73 lakhs in Q1 FY25, a growth of about 13%. Profit after tax jumped sharply to ₹42.15 lakhs from ₹4.71 lakhs in the year-ago quarter, driven by lower other expenses and better operating margins. For the full FY25, the company posted revenue of ₹2,199.90 lakhs and PAT of ₹202.26 lakhs. The statutory auditor (Sarda Soni Associates LLP) issued an unmodified limited review opinion on both standalone and consolidated results. The company also acquired the business of its associate Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for ₹13 lakhs, effective June 30, 2025, and appointed Dr. Alaka Keshav Deshpande as an Additional Woman Independent Director.
The sharp jump in quarterly profit and turnaround in operating performance are positive signals for shareholders, though revenue growth of ~13% is modest. The acquisition from a related associate and new board appointment indicate ongoing restructuring, which investors should watch for further business updates.